AAT

Sector Update: Healthcares

Healthcare shares were generally lower in pre-market trade on Friday.

In healthcare stocks news, Kamada ( KMDA ) is lower after the company announced preliminary top-line results from the Phase II/III pivotal clinical trial in Europe and Canada of its proprietary inhaled Alpha-1 Antitrypsin ( AAT ) therapy to treat Alpha-1 Antitrypsin Deficiency (AATD or inherited emphysema).

And, Abbott ( ABT ) edged lower in recent pre-market trading on Friday after saying it has signed a definitive agreement to buy Latin American pharmaceutical company CFR Pharmaceuticals for approximately $2.9 billion, plus the assumption of debt of approximately $430 million.

ABT closed down to $39.24 Thursday, in a 52-week range of $32.70 - $40.49.

And, Bovie Medical ( BVX ) said late Thursday that Q1 sales were $6.5 million, up 14% from a year ago. Adjusted net loss was $0.01 per share, down from a loss of $0.02 last year.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.